Business
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
- Conference Call and Live Audio Webcast Scheduled for August 8, 2024 - PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"- Conference Call and Live Audio Webcast Scheduled for August 8, 2024 -\nPURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Thursday August 8, 2024 before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference CallDate / TimeAugust 8, 2024 at 8:30am ET / 5:30am PTTelephone Access: US/Canada Participant Toll-Free Dial-in Number: (800) 715-9871US/Canada Participant International Dial-In Number: (646) 307-1963Conference ID Number: 3702003Webcast Access:The audio webcast with live Q&A will be accessible at https://edge.media-server.com/mmc/p/3napeebe or via the Investor Relations section of Cognition’s website. An archive of the webcast and presentation will be available for 90 days beginning at approximately 10:30 a.m. ET on August 8, 2024. About Cognition Therapeutics:Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-look...